Inovio Pharmaceuticals (NASDAQ:INO – Get Free Report) released its quarterly earnings data on Monday. The biopharmaceutical company reported ($1.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.08) by ($0.23), RTT News reports. Inovio Pharmaceuticals had a negative net margin of 16,238.91% and a negative return on equity of 80.79%. During […]
StockNews.com upgraded shares of Inovio Pharmaceuticals (NASDAQ:INO – Free Report) from a sell rating to a hold rating in a report released on Monday. Several other research analysts have also weighed in on the company. Oppenheimer upgraded Inovio Pharmaceuticals from a market perform rating to an outperform rating and set a $4.00 target price on […]
Beck Bode LLC purchased a new position in shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO – Get Rating) in the 4th quarter, HoldingsChannel.com reports. The fund purchased 27,226 shares of the biopharmaceutical company’s stock, valued at approximately $42,000. Several other hedge funds have also added to or reduced their stakes in INO. MetLife Investment Management LLC […]